Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131643 | 0.88 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4285891 | 0.87 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4135765 | 0.85 | L3MBTL3 (0.70) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4130764 | 0.84 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1HRH3HRH4MBTD1 | |
| SCHEMBL4130526 | 0.84 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1HRH3HRH4MBTD1 | |
| SCHEMBL4292175 | 0.82 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4137331 | 0.81 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4280878 | 0.81 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4292098 | 0.81 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4127955 | 0.80 | HRH3 (0.47) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | L3MBTL3 2655/4885L3MBTL1 2620/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.